Back Pain Treatment: A Review of the 2018 Recommendations
ARTICLE PDF (Українська)


tolperisone hydrochloride, back pain, back pain, multimorbidity, polypharmacotherapy, treatment of acute pain, treatment of chronic pain

How to Cite

Svyrydova, N. (2018). Back Pain Treatment: A Review of the 2018 Recommendations. East European Journal of Neurology, (3(21), 33-43.


In 2018, published works that focus on European and American recommendations for the treatment of chronic back pain, where using opioid analgesics, it is recommended to take into account their complexity in multimorbid pathology in patients, since there is no effectiveness of pain reduction due to polypharmacotherapy. The peculiarity of the treatment is that the prevalence of musculoskeletal pain more often reaches its peak in elderly patients and is about 60%, which allows to establish an important direction in therapy - taking into account multimorbid pathology. It is necessary to take into account the accompanying chronic pathology because in patients with back pain hypertension occurs in 58.7%, chronic kidney disease occurs in 29.1% of patients, diabetes mellitus occurs in 23.1% of patients, depressive disorders occur in 15 , 3% of patients. Today it is proved that the common use of NSAIDs is critical for adverse events on the part of their use in patients with multimorbid pathology. In a number of clinical studies, the significant effect of tolperisone has been proven to relieve muscular spasm in acute and chronic back pain compared to tizanidine, where tolperisone is more often used in multimorbid pathology as a relaxant of skeletal muscles. The combination therapy strategy potentially represents a paradigm shift in rehabilitation therapy and can be very important for early intervention in spasticity management processes. In order to expand the scope of potential therapeutic use, the basic requirement for safe treatment is the quantitative basis of evidence of safety and efficacy, which, for example, is now presented in full on tolperisone hydrochloride. The new therapeutic options include a progressive addition of convergent therapy, where it is assumed that the potential for therapeutic purposes will be strengthened in view of the multimorbid pathology in the patient with back pain.
ARTICLE PDF (Українська)


1. Muller-Schwefe GH. (2011) European survey of chronic pain patients: results for Germany. Curr Med Res Opin., no 27(11), pp. 2099–106.
2. Brochet B, Michel P, Barberger-Gateau P, Dartigues JF. (1998) Population-based study of pain in elderly people: a descriptive survey., Age and Ageing., no 27(3), pp. 279–84.
3. Grimby C, Fastbom J, Forsell Y, Thorslund M, Claesson CB, Winblad B. (1999) Musculoskeletal pain and analgesic therapy in a very old population. Arch Gerontol Geriatr., no 29(1), pp. 29–43.
4. van den Bussche H, Schon G, Kolonko T, Hansen H, Wegscheider K, Glaeske G, et al. Patterns of ambulatory medical care utilization in elderly patients with special reference to chronic diseases and multimorbidity—results from a claims data based observational study in Germany. (2011) BMC Geriatr., no 11(1), pp. 54.
5. Gunn JM, Ayton DR, Densley K, Pallant JF, Chondros P, Herrman HE, et al. (2012) The association between chronic illness, multimorbidity and depressive symptoms in an Australian primary care cohort. Soc Psychiatry Psychiatr Epidemiol., no Epub 2010/12/25.
6. van Oostrom SH, Picavet HS, van Gelder BM, Lemmens LC, Hoeymans N, van Dijk CE, et al. (2012) Multimorbidity and comorbidity in the Dutch population—data from general practices. BMC Public Health., no 12(1), pp.715.
7. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. (2012) Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet., no 380(9836), pp. 37–43.
8. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, et al. (2009) Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain., no 10(2), pp. 113–30.
9. Schafer I. (2012) Does multimorbidity influence the occurrence rates of chronic conditions? A claims data based comparison of expected and observed prevalence rates. PLoS One., no 7(9), pp.453-90
10.World Health Organization. Cancer pain relief, with a guide to opioid availability. Geneva: WHO; 1996:2nd edition.
11. Smith H, Bruckenthal P. (2010) Implications of opioid analgesia for medically complicated patients. Drugs Aging., no 27(5), pp. 417–33.
12. Enke O., H. A. New, C. H. New, S. Mathieson, A. J. McLachlan, et al. (2018) Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis. CMAJ., noJul 3; 190(26), pp.786–793.
13. Schmidt PC, Ruchelli G, Mackey SC, et al. (2013)Perioperative gabapentinoids: choice of agent, dose, timing, and effects on chronic postsurgical pain. Anesthesiology., no 119., p. 1215–21.
14. Atkinson JH, Slater MA, Capparelli EV, et al. (2016) A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating component. Pain., no 157, pp.1499–507
15. Baron R, Freynhagen R, Tolle TR, et al. (2010) A0081007 Investigators. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain., no 150., pp.420–7.
16. Khoromi S, Patsalides A, Parada S, et al. (2005)Topiramate in chronic lumbar radicular pain. JPain., no 6., pp.829–36.
17. Markman JD, Frazer ME, Rast SA, et al.(2015) Double-blind, randomized, controlled, crossover trial of pregabalin for neurogenic claudication. Neurology., no 84., pp.265–72.
18. Mathieson S, Maher CG, McLachlan AJ, et al. (2017) Trial of pregabalin for acute and chronic sciatica. NEnglJMed., no 376., pp.1111–20.
19. McCleane GJ.(2000) Gabapentin reduces chronic benign nociceptive pain: A double-blind, placebo-controlled cross-over study. PainClin., no.12., pp. 81–5.
20. McCleane GJ.(2001) Does gabapentin have an analgesic effect on background, movement and referred pain? Arandomised, double-blind, placebocontrolledstudy. PainClin., no13., pp.103–7
21. Inovay J., Katona J. Several years of observation with Mydeton in the treatment of lockjaw. Ther. Hung (Hung Med. J.). 1991; 39 (4): 185–187.
22. Yildirim K, Şışecıoğlu M, Karatay S, et al. (2003)The effectiveness of gabapentin in patients with chronic radiculopathy. Pain Clin., no 15., pp.213–8.
23. Australian Medicines Handbook. Adelaide (Australia): Australian Medicines Handbook Pty Ltd; 2017. Available: (accessed 2017 Sept. 9)
24. Mathieson S, Valenti L, Maher CG, et al. (2018) Worsening trends in analgesics recommended for spinal pain in primary care. Eur Spine J., no 27., pp.1136–45.
25. Goodman CW, Brett AS. (2017) Gabapentin and pregabalin for pain — Is increased prescribing a cause for concern? N Engl J Med., no 377, pp.411–4.
26. Shmagel A, Ngo L, Ensrud K, Foley R.Prescription Medication Use Among Community-Based U.S. Adults With Chronic Low Back Pain: A Cross-Sectional Population Based Study. J Pain., no Apr 17. (18)30145-7.
27. Koval'chuk V.V, Skoromets A.A, Vasil'eva I.V. (2008) Comparative efficacy of different muscle relaxants in the rehabilitation of post-stroke patients with spasticity. Zh Nevrol Psikhiatr Im S S Korsakova., no 108., pp.14–19.
28.Stamenova P, Koytchev R, Kuhn K, et al. (2005)A randomized, double-blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke., Eur J Neurol., no 12., pp. 453–461.
29.Stamenova P, Koytchev R, Kuhn K, et al. (2006) A randomized, double blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. Zh Nevrol Psikhiatr Im S S Korsakova., no106, pp. 34–42.
30.Svensson P, Wang K, Arendt-Nielsen L. (2003) Effect of muscle relaxants on experimental jaw-muscle pain and jaw-stretch reflexes: a double-blind and placebo-controlled trial.Eur J Pain., no 7., pp449–456.
33. Кукушкин М.Л. (2013) Современный взгляд на механизм действия мидокалма. Жур. Лечебное дело, no 2 (30), рр.7-13
34. Hofer D., Lohberger B., Steinecker B. et al. (2006)A comparative study of the action of tolperisone on seven different voltage dependent sodium channel isoforms.Eur. J. Pharmacol., no 538 (1–3), pp. 5–14
35. Furuta Y., Yoshikawa A. (1976) Reversible adrenergic alpha-receptor blocking action of 2,48-dimethyl-3-piperidino-propiophenone (tolperisone).,Jpn. J. Pharmacol., no 26, pp. 543–550.
36. Abranyi I. (1988) Study on the effect of 150-mg Mydocalm coated tablets in peripheral vascular diseases and in myotonias of various origin., Hung Med. J., no36 (2), pp. 56–61.
37. Брискин Б.С., Дибиров М.Д., Евсеев Ю.Н. и др. (2000) Лечение хронической артериальной недостаточности нижних конечностей Мидокалмом у больных пожилого и старческого возраста.,Хирургия., no 4, pp. 52–54.
38. Брискин Б.С., Сакунова Т.И., Прошин А.В. и др. (2000) Мидокалм в комплексном лечении больных с синдромом диабетической стопы., Клин. геронтология.,no 34, pp. 34–38
39. Dulin J., Kovacs L., Ramm S. et al. (1998) Evaluation of sedative effects of single repeated doses of 50 mg and 150 mg Tolperisone Hydrochloride. Results of prospective, randomized, double-blind, placebo-control trial., Pharmacopsychiatry., no 31(4), pp. 136–141
40. Fay V., Szakonyi T., Urban E. et al. (1998) Neck and low back pain in the post-menopause., Rehabilitation., no 8(1), pp. 26–28.
41. 27. Pratzel H.G., Alken R.G., Ramm S. (1996) Efficacy and tolerance of repeated doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo controlled double-blind trial., Pain., no 67, pp.417–425
42. Feher M., Lantos A., Denes Z. et al. (2003) Опыт длительного применения препарата Мидокалм.,Провизор., no7. URL:
43. Міщенко Т.С., Харіна К.В. (2015) Постінсультний больовий синдром.Основні аспекти діагностики та ефективність сучасних методів лікування, Міжнар.неврол.журнал,no 5(75), pp. 15–20
44. Дзяк Л.А., Цуркаленко Е.С., Сайков Н.Н. (2015)Возможности комплексной реабилитации пациентов, перенесших позвоночно-спинномозговую травму, Міжнар.неврол.журнал, no 6(76), pp. 120–126
45. Agarwal S, Patel T, ShahN, Patel B.(2017) Comparative study of therapeutic response to baclofen and tolperisonein spasticity., Biomed Pharmacother., no Mar, 87., pp.628-635.
46. Pratzel HG1, Alken RG, Ramm S (1996) Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo-controlled double-blind trial.,Pain., no Oct;67(2-3)., pp. 417-25.
47. Bose P, Hou J, Nelson R, Nissim N, Parmer R, Keener J. et al. Effects of acute intrathecal baclofen in an animal model of TBI-induced spasticity, cognitive, and balance disabilities.J Neurotrauma.2013;30:1177–1191.
48. Ramlackhansingh A.F, Brooks D.J, Greenwood R.J, Bose S.K, Turkheimer F.E, Kinnunen K.M. et al. Inflammation after trauma: Microglial activation and traumatic brain injury.Ann Neurol.2011;70:374–383.
49. Katz R.T, Rymer W.Z. Spastic hypertonia: Mechanisms and measurement.ArchPhys Med Rehabil.1989;70:144–155.
50. Roy R.R, Edgerton V.R. Neurobiological perspective of spasticity as occurs after a spinal cord injury.Exp Neurol.2012;235:116–122.
51. Schindler-Ivens S, Shields R.K. Low frequency depression of H-reflexes in humans with acute and chronic spinal-cord injury.Exp Brain Res.2000;133:233–241.
52. Little J.W, Ditunno J.F Jr, Stiens S.A, Harris R.M. Incomplete spinal cord injury: Neuronal mechanisms of motor recovery and hyperreflexia.ArchPhys Medic Rehabil.1999;80:587–599.
53. Nielsen J, Petersen N, Crone C. Changes in transmission across synapses of Ia afferents in spastic patients.Brain.1995;118(Pt 4):995–1004.
54. Bennett D.J, Li Y, Siu M. Plateau potentials in sacrocaudalmotoneurons of chronic spinal rats, recorded in vitro.J Neurophysiol.2001;86:1955–1971.
55. Yates C.C,Charlesworth A, Reese N.B, Ishida K, Skinner R.D, Garcia-Rill E. Modafinil normalized hyperreflexia after spinal transection in adult rats.Spinal Cord.2009;47:481–485.
56. Heckmann C.J, Gorassini M.A, Bennett D.J. Persistent inward currents in motoneuron dendrites: Implications for motor output.Muscle Nerve.2005;31:135–156.
57. Shapiro S. Neurotransmission by neurons that use serotonin, noradrenaline, glutamate, glycine, and gamma-aminobutyric acid in the normal and injured spinal cord.Neurosurgery.1997;40:168–176.
58. Kobeissy FH (2015) Brain Neurotrauma: Molecular, Neuropsychological, and Rehabilitation Aspects. Boca Raton (FL): CRC Press/Taylor & Francis; 2015.
59. Rao R., Panghate A., Chandanwale A. et. al (2012) Clinical Comparative Study: Efficacy and Tolerability of Tolperisone and Thiocolchicoside in Acute Low Back Pain and Spinal Muscle Spasticity. Asian Spine J, no 6(2)., pp. 115–122.
60. Pratzel HG, Alken RG, Ramm S. Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo-controlled double-blind trial. Pain. 1996;67:417–425.
61. Quasthoff S, Möckel C, Zieglgänsberger W, Schreibmayer W. Tolperisone: a typical representative of a class of centrally acting muscle relaxants with less sedative side effects. CNS Neurosci Ther. 2008;14:107–119
62. Bajaj P, Arendt-Nielsen L, Madeleine P, Svensson P. Prophylactic tolperisone for post-exercise muscle soreness causes reduced isometric force: a double-blind randomized crossover control study. Eur J Pain. 2003;7:407–418
63. Ono H, Fukuda H, Kudo Y. Mechanisms of depressant action of muscle relaxants on spinal reflexes: participation of membrane stabilizing action. J Pharmacobiodyn. 1984;7:171–176.
64. Cabitza P, Randelli P. Efficacy and safety of eperisone in patients with low back pain: a double blind randomized study. Eur Rev Med Pharmacol Sci. 2008;12:229–235
65. van den Akker M, Buntinx F, Metsemakers JF, Roos S, Knottnerus JA. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol. 1998;51(5):367–75.
66. O'Halloran J, Miller GC, Britt H. Defining chronic conditions for primary care with ICPC-2. Fam Pract. 2004;21(4):381–6.
67. Guthrie B, McCowan C, Davey P, Simpson CR, Dreischulte T, Barnett K. High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice. BMJ. 2011;342:d3514
68. Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F, Group EGW. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23 Suppl 7:vii139–54
69. Gosch M. [Analgesics in geriatric patients. Adverse side effects and interactions]. Z Gerontol Geriatr. 2015;48(5):483–92; quiz 93.
70. Turtle EJ, Dear JW, Webb DJ. A systematic review of the effect of paracetamol on blood pressure in hypertensive and non-hypertensive subjects. Br J Clin Pharmacol. 2013;75(6):1396–405.
71. Gualtierotti R, Zoppi A, Mugellini A, Derosa G, D'Angelo A, Fogari R. Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan and aliskiren in hypertensive patients. Expert Opin Pharmacother. 2013;14(14):1875–84.
72. Dubovsky AN, Arvikar S, Stern TA, Axelrod L. The neuropsychiatric complications of glucocorticoid use: steroid psychosis revisited. Psychosomatics. 2012;53(2):103–15.
73. Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010. BMC Med. 2015;13:74
74. Guthrie B, Payne K, Alderson P, McMurdo ME, Mercer SW. Adapting clinical guidelines to take account of multimorbidity. BMJ. 2012;345:e6341
75. Jiang HY, Chen HZ, Hu XJ, Yu ZH, Yang W, Deng M, et al. (2015)Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. , no 13(1)., pp.42–50 .
76. Galos G. Several years observations with Mydocalm muscle relaxant in locomotor disease patients // Тher. Hung (Hung Med. J.) 1992; 40 (2): 69–71. 23.
77. Porkolab E. Dose reduction possibilities of non-steroidal antiphlogistics in locomotor patients by Mydocalm // Magyar. Belorv. 1992; Arch Suppl. 45 (3): 138–141.